韩波
韩波，男，教授，博士生导师。现担任药学院副院长。2003年毕业于四川大学华西药学院，获学士学位，2010年毕业于四川大学华西药学院，获得药物化学博士学位。2011年破格晋升为副高级职称，2015年破格晋升为研究员。2017年受国家留学基金委资助以访问学者赴美国纽约州立大学rna研究所工作。
全国百篇优秀博士论文奖获得者，四川省杰出青年基金，教育部科技评价与评审信息系统评审专家，国家自然基金通讯评审专家，四川省科技专家库专家，“全国大学生药苑论坛”项目评审专家。入选四川省学术与技术带头人后备人选，四川省中医药管理局学术技术带头人后备人选，四川省卫生计生委学术技术带头人后备人选，全国高等中医药院校优秀青年，成都市青年联合会常委，成都中医药大学讲席教授；current topics in medicinal chemistry期刊客座主编；chemical reviews、chemical communications、organic letters、advanced synthesis & catalysis 等十余种国际知名期刊的同行审稿人。
研究方向为中药药效物质的分子网络机制、结构优化、多维构效关系和创新药物研发。以临床疗效显著的经典中药药效成分为研究对象，融合多层次的药物结构信息与活性数据，系统研究药效成分“构-效-毒”的多维关系，以此开展药物筛选和创新药物设计开发。
目前主持国家自然科学基金3项、十三五“重大新药创制”科技重大专项、教育部百篇优秀博士论文基金、四川省科技重大前沿项目等十余项国家及省部级科研项目。获得“四川省杰出青年基金”、“中国博士后科学基金特助”等人才项目资助。以第一作者或通讯作者发表sci收录的论文32篇，其中一作或通讯作者论文中：if大于10论文3篇，if大于5论文21篇，学科领域一区论文16篇，引用次数大于100论文2篇，esi高被引论文1篇。获得授权发明专利13项；出版专著5部；参与制定国际标准1项。
※主持项目：
1. 2018～2020，中药防治耐药菌创新结构药物研发，“重大新药创制”十三五科技重大专项，负责人
2. 2018～2021，马钱子生物碱诱导程序性细胞死亡的“效与毒”整合作用机制以及立体构效关系研究，国家自然科学基金面上项目，负责人
3. 2016～2019，钩藤生物碱调控α-突触核蛋白依赖的自噬-溶酶体途径治疗帕金森病的作用机制和构效关系研究，国家自然科学基金面上项目，负责人
4. 2017～2020，中药防治耐药菌新品种筛选及关键创新技术建立，四川省科技厅研究重大前沿项目，负责人
5. 2014～2016，基于“立体构效关系模型”融合生物信息学研究青黛治疗慢粒白血病的药效物质基础和分子机制，四川省科技厅杰出青年基金，负责人
6. 2014～2016，基于双催化体系不对称合成结构多样性杂环骨架，国家自然科学基金青年基金，负责人
7. 2014～2018，立体选择性构建结构多样性的药物骨架，全国百篇优秀博士论文作者专项基金，负责人
8. 2013～2014，基于生物信息学研究大青叶治疗cml的药效物质基础，中国博士后科学基金特别资助项目，负责人
9. 2012～2014，新型紫杉醇衍生物的设计、合成及活性研究，教育部博士学科点专项科研基金，负责人
10. 2017～2021，附子”毒与效“的多维评价与整合分析研究，国家自然科学基金重点项目，主研人员
※代表性研究论文：
[1] xie, x., huang, w., peng, c.*, han, b.* organocatalytic asymmetric synthesis of six-membered carbocycle-based spiro compounds. adv. synth. catal. 2018, 360(2), 194-228. if: 5.123
[2] he, x. h., yang, l., ji, y. l., zhao, q., yang, m. c., huang, w., peng, c.,* han, b.* chemo- and stereoselective cross rauhut-currier-type reaction of tri-substituted alkenes containing trifluoromethyl groups. chem. eur. j. 2018, 24(8), 1947-1955. if: 5.160
[3] zhang, y., wang, c., huang, w., haruehanroengra, p., peng, c.*, sheng, j., han, b.*, he, g.* application of organocatalysis in bioorganometallic chemistry: asymmetric synthesis of multifunctionalized spirocyclic pyrazolone–ferrocene hybrids as novel rala inhibitors. org. chem. front. 2018, 5(14), 2229-2233. if: 5.455
[4] wang, x. y., wu, f. b., li, g. y., zhang, n., song, x. r., zheng, y., gong, c. y., han, b.*, he, g.* lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siulk1 in hepatocellular carcinoma therapy. actabiomater. 2018, 74, 414-429. if: 6.383
[5] leng, h.-j., li, q. z., zeng, r., dai, q. s., zhu, h. p., liu, y., huang, w., han, b.*, li, j. l.* asymmetric construction of spiropyrazolone skeletons via amine-catalyzed [3 3] annulation. adv. synth. catal. 2018, 360(2), 229-234. if: 5.123
[6] tang, x., gao, y. j., deng, h. q., lei, j. j., liu, s. w., zhou, l., shi, y., liang, h., qiao, j., guo, l., han, b.*, cui, h. l.* catalyst-free [3 2] cyclization of dihydroisoquinoline imines and isatin-derived morita-baylis-hillman carbonates via 1,5-electrocyclization: synthesis of tetrahydroisoquinoline-fused spirooxindoles. org. biomol. chem. 2018, 16(18), 3362-3366. if: 3.423
[7] cao, c., huang, w., zhang, n., wu, f. b. *, xu, t., pan, x. l., peng, c.*, han, b.* narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the ampk-ulk1 axis. cell prolif. 2018, doi:10.1111/cpr.12518. if: 4.936
[8] zhao, q., peng, c.*, huang, h., liu, s. j., zhong, y. j., huang, w., he, g., han, b.* asymmetric synthesis of tetrahydroisoquinoline-fused spirooxindoles as ras-gtp inhibitors that inhibit colon adenocarcinoma cell proliferation and invasion. chem. commun.2018, 54(60), 8359-8362. if: 6.290
[9] yang, m. c., peng, c.*, huang, h., yang, l., he, x. h., huang, w., cui, h. l., he, g., han, b.* organocatalytic asymmetric synthesis of spiro-oxindole piperidine derivatives that reduce cancer cell proliferation by inhibiting mdm2-p53 interaction. org. lett. 2017, 19(24), 6752-6755. if: 6.492
[10] tang, x., yang, m. c., ye, c., liu, l., zhou, h. l., jiang, x. j., you, x. l., han, b.*, cui, h. l.* catalyst-free [3 2] cyclization of imines and morita–baylis–hillman carbonates: a general route to tetrahydropyrrolo [2,1-a] isoquinolines and dihydropyrrolo [2,1-a] isoquinolines. org. chem. front. 2017, 4(11), 2128-2133. if: 5.455
[11] li, x., huang, w., liu, y. q., kang, j. w., xia, d., he, g., peng, c.*, han, b.* control of activation mode to achieve diastereodivergence in asymmetric syntheses of chiral spiropiperidinone derivatives. j. org. chem. 2017, 82(1), 397-406. if: 4.805
[12] wang, b., huang, w., zhou, j., tang, x., chen, y., peng, c.*, han, b.* drug design based on pentaerythritol tetranitrate reductase: synthesis and antibacterial activity of pogostone derivatives. org. biomol. chem. 2017, 15(31), 6548-6556. if: 3.423
[13] yang, l., huang, w., he, x. h., yang, m. c., li, x., he, g., peng, c.*, han, b.* stereoselective synthesis of hydropyrano [3,2-b] indolesviaorganocatalytic asymmetric inverse-electron-demand oxa-diels- alder reaction. adv. synth. catal. 2016, 358(18), 2970-2975. if: 5.123
[14] leng, h. j., peng, f., zingales, s., huang, w., wang, b., zhao, q., he, g., peng, c.*, han, b.* core-scaffold-inspired asymmetric synthesis of polysubstituted chiral hexahydropyridazines that potently inhibit breast cancer cell proliferation by inducing apoptosis. chem. eur. j. 2015, 21(50), 18100-18108. if: 5.160
[15] zhou, r., wu, q. j., guo, m. r., huang, w., he, x. h., yang, l., peng, f., he, g., han, b.* organocatalytic cascade reaction for the asymmetric synthesis of novel chroman-fused spirooxindoles that potently inhibit cancer cell proliferation. chem. commun.2015, 51(66), 13113-13116. if: 6.290
[16] han, b., huang, w., ren, w., he, g., wang, j. h., peng, c.* asymmetric synthesis of cyclohexane-fused drug-like spirocyclic scaffolds containing six contiguous stereogenic centersviaorganocatalytic cascade reactions. adv. synth. catal. 2015, 357(2-3), 561-568. if: 5.123
[17] han, b., xie, x., huang, w., li, x., yang, l., peng, c.* organocatalytic morita- baylis-hillman/michael/acetalization cascade: procedure-controlled diastereodivergence in the asymmetric synthesis of fully substituted tetrahydropyrans. adv. synth. catal.2014, 356(17), 3676-3682. if: 5.123
[18] he, g., wu, f. b., huang, w., zhou, r., ouyang, l., han, b.* one-pot asymmetric synthesis of substituted tetrahydrofuransviaa multicatalytic benzoin/michael/acetalization cascade. adv. synth. catal. 2014, 356(10), 2311-2319. if: 5.123
[19] li, x., yang, l., peng, c.*, xie, x., leng, h. j., wang, b., tang, z. w., he, g., ouyang, l., huang, w., han, b.* organocatalytic tandem morita-baylis-hillman-michael reaction for asymmetric synthesis of a drug-like oxa-spirocyclic indanone scaffold. chem. commun. 2013, 49(77), 8692-8694. if: 6.290
[20] xie, x., peng, c.*, he, g., leng, h. j., wang, b., huang, w., han, b.* asymmetric synthesis of a structurally and stereochemically complex spirooxindole pyran scaffold through an organocatalytic multicomponent cascade reaction. chem. commun. 2012, 48(85), 10487-10489. if: 6.290
[21] han, b., xiao, y. c., yao, y., chen, y. c.* lewis acid catalyzed intramolecular direct ene reaction of indoles. angew. chem. int. ed. 2010, 49(52), 10189-10191. if: 12.102
[22] han, b., xiao, y. c., zhao, q. h., chen, y. c.* asymmetric michael addition of γ,γ-disubstituted α,β-unsaturated aldehydes to nitroolefins via dienamine catalysis. org. lett. 2009, 11(20), 4660-4663. if:6.492
[23] han, b., he, z. q., li, j. l., li, r., jiang, k., liu, t. y., chen, y. c.* organocatalytic regio- and stereoselective inverse-electron-demand aza-diels-alder reaction of α,β-unsaturated aldehydes and n-tosyl-1-aza-1,3-butadienes. angew. chem. int. ed. 2009, 48(30), 5474-5477. if: 12.102
[24] han, b., li, j. l., ma, c., zhang, s. j., chen, y. c.* organocatalytic asymmetric inverse-electron-demand aza-diels-alder reaction of n-sulfonyl-1-aza-1,3-butadienes and aldehydes. angew. chem. int. ed. 2008, 47(51), 9971-9974. if: 12.102
[25] han, b., liu, q. p., li, r., tian, x., xiong, x. f., deng, j. g., chen, y. c.* discovery of bifunctional thiourea/secondary-amine organocatalysts for the highly stereoselective nitro-mannich reaction of α-substituted nitroacetates. chem. eur. j. 2008, 14(27), 8094-8097. if: 5.160
※授权专利：
1. 多取代基类型的γ-吡喃并吡咯烷酮化合物及制备方法和用途 ，zl201610081072.2，发明专利
2. 巴比妥酸手性环己烷螺环化合物及其制备方法与用途，zl201510036802.2，发明专利
3. 一种四氢吡喃醇系列手性化合物及其合成方法和用途，zl201410415790.x，发明专利
4. 一种化合物晶型，zl201410415634.3，发明专利
5. 茚酮内盐衍生物及其晶型和它们的制备方法与用途，zl201510191363.2，发明专利
6. 一种1,3-茚满二酮衍生物及其晶型，zl201510191738.5，发明专利
7. 一种化合物的拆分方法，zl201410415353.8，发明专利
8. 罗丹宁手性环己烷螺环化合物的晶型及其制备方法与用途，zl201510072781.x，发明专利
9. 茚满二酮手性环己烷螺环化合物及其制备方法与用途，zl201510037231.4，发明专利
10. 罗丹宁手性环己烷螺环化合物及其制备方法与用途，zl201510036832.3，发明专利
11. 一种呋喃内酯环类衍生物的晶型，zl201410110978.3，发明专利
12. 呋喃内酯环类衍生物及其用途，zl201410110990.4，发明专利
13. 含季碳手性中心的呋喃内酯环类化合物的合成方法，zl201410115288.7，发明专利
※奖励及学术任职：
1. 全国百篇优秀博士论文奖，教育部，国务院学位委员会，2014
2. 全国高等中医药院校“优秀青年”，全国高等中医药院校青年研究会，2016
3. 全国大学生“药苑论坛“创新成果一等奖，教育部高等学校药学类专业教学指导委员会，2015
4. 四川省学术与技术带头人后备人选，2014
5. curr. top. med. chem. 期刊，客座主编，2016
6. 成都市青年联合会，常委，2016
7. 四川省卫生计生委学术技术带头人后备人选，2016
8. 四川省中医药管理局学术技术带头人后备人选，2017
9. 世界中医药学会联合会“中药上市后再评价专业委员会”，常务理事，2017